MBOT vs STXS
MBOT: Microbot Medical develops compact, disposable, and remotely operated robotic systems designed to modernize minimally invasive endovascular surgery. STXS: Stereotaxis provides advanced robotic magnetic navigation systems that enhance the precision, safety, and efficiency of minimally invasive endovascular and electrophysiology procedures.
Side-by-side fundamentals
| Metric | MBOT | STXS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $0.9475 | $0.9983 | |
| Market cap | $64M | $100M | |
| Net margin FY2025, SEC XBRL | n/a | -66.8% | |
| Gross margin FY2025, SEC XBRL | n/a | +52.7% | |
| Operating margin FY2025, SEC XBRL | n/a | -68.3% | |
| ROE FY2025, SEC XBRL | -16.9% | -160.5% | MBOT higher |
| ROA FY2025, SEC XBRL | -16.1% | -41.4% | MBOT higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +20.3% | |
| Revenue CAGR (3y) SEC XBRL | -56.0% | +4.8% | STXS higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.52 | 1.39 | |
| 1-year return as of 2026-10-20 close | -66.2% | -67.8% | MBOT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.